ADGRB1 and cancer: Collectively, these provide evidence that the TSRs in BAI1 bind to both CD36 and αvβ5 integrin receptors and inhibit angiogenesis, providing evidence that the BAI1 is an attractive therapeutic target for cancer therapy.